Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine vs Caudal Block for Renal Protection in Pediatric Nephrectomy
NCT05271253Phase 3Completed
- Sponsor
- Alexandria University
- Start
- Apr 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexmedetomidine in acute kidney injury (AKI) (3 arms), sponsored by Alexandria University. Primary endpoints: Serum Cystatin C and Serum Neutrophil Gelatinase-Associated Lipocalin. Started Apr 2021; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT05271253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05271253.